The researchers’ attention was directed toward the safety of the COVID-19 vaccine, particularly in patients with HS being treated with the only drug approved for the condition to date, adalimumab (anti TNF-alpha) [116,117]. The gene discussed is TNF; the disease is histiocytic sarcoma.